Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Lawitz EJ, Poordad F, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515-523.

Publication Type:

Journal Article

Authors:

E J Lawitz; Fred Poordad; Pang, P.S.; Hyland, R.H.; Ding, X.; Mo, H.; Symonds, W.T.; J G McHutchison; Membreno, F.E.

Source:

Lancet, Volume 383, Issue 9916, p.515-523 (2014)

Keywords:

Adult, Cities, clinical trial, Clinical Trials, contraindications, Genotype, genotype 1, HCV, Headache, Health, hepatitis, Hepatitis C, hepatitis C virus, history, Infection, Intention, Liver, Lost to Follow-Up, methods, Nausea, NS5A inhibitor, Patients, protease inhibitor, psychiatric, Research, Research Support, Ribavirin, Safety, sofosbuvir, Texas, treatment, treatment-naive

Cited On:

Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/24209977

Export Citation:

RIS Format

Top